Victor L Villemagne Selected Research

florbenazine F 18

11/2017	Management Impact of Imaging Brain Vesicular Monoamine Transporter Type 2 in Clinically Uncertain Parkinsonian Syndrome with 18F-AV133 and PET.
1/2012	Differential diagnosis in Alzheimer's disease and dementia with Lewy bodies via VMAT2 and amyloid imaging.
7/2011	In vivo assessment of vesicular monoamine transporter type 2 in dementia with lewy bodies and Alzheimer disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Victor L Villemagne Research Topics

Disease

183	Alzheimer Disease (Alzheimer's Disease) 11/2022 - 08/2005
96	Cognitive Dysfunction 10/2022 - 11/2008
69	Dementia (Dementias) 10/2022 - 08/2007
26	Atrophy 05/2022 - 03/2010
16	Disease Progression 01/2022 - 07/2012
9	Parkinson Disease (Parkinson's Disease) 10/2021 - 09/2009
8	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2022 - 03/2012
7	Frontotemporal Dementia (Semantic Dementia) 01/2018 - 09/2011
6	Gliosis 10/2022 - 04/2005
6	Amyloid Plaque 01/2021 - 01/2010
5	Amyloidosis 01/2022 - 01/2013
4	Tauopathies 01/2021 - 01/2014
4	Parkinsonian Disorders (Parkinsonism) 01/2021 - 11/2017
4	Primary Progressive Aphasia 11/2018 - 10/2015
4	Proteostasis Deficiencies 07/2018 - 11/2009
3	Corticobasal Degeneration 01/2021 - 10/2015
3	Cerebrovascular Disorders (Cerebrovascular Occlusion) 01/2020 - 04/2014
3	Ischemic Stroke 01/2016 - 12/2010
2	Schizophrenia (Dementia Praecox) 10/2021 - 01/2006
2	Cerebral Amyloid Angiopathy (Congophilic Angiopathy) 01/2021 - 12/2010
2	Neuroinflammatory Diseases 01/2021 - 04/2013
2	Obstructive Sleep Apnea 01/2020 - 01/2018
2	Traumatic Brain Injuries (Traumatic Brain Injury) 01/2020 - 06/2014
2	Neoplasms (Cancer) 10/2018 - 01/2018
2	Memory Disorders (Memory Loss) 11/2017 - 03/2011
2	Vascular Dementia (Subcortical Arteriosclerotic Encephalopathy) 05/2015 - 08/2011
2	Hemorrhage 01/2014 - 12/2010
2	Frontotemporal Lobar Degeneration (Degeneration, Frontotemporal Lobar) 10/2012 - 08/2011
1	Prodromal Symptoms 01/2022
1	Progressive Supranuclear Palsy (Steele Richardson Olszewski Syndrome) 01/2022
1	Insulin Resistance 01/2022
1	Coronary Artery Disease (Coronary Atherosclerosis) 01/2022
1	Inflammation (Inflammations) 10/2021
1	Vascular Diseases (Vascular Disease) 09/2021
1	Down Syndrome (Down's Syndrome) 01/2021

Drug/Important Bio-Agent (IBA)

156	Amyloid (Amyloid Fibrils)IBA 10/2022 - 11/2008
94	Biomarkers (Surrogate Marker)IBA 11/2022 - 02/2006
30	Amyloid beta-PeptidesIBA 02/2022 - 04/2005
26	Apolipoproteins E (ApoE)IBA 11/2022 - 01/2011
25	2- (4'- (methylamino)phenyl)- 6- hydroxybenzothiazole (Pittsburgh compound B)IBA 01/2022 - 04/2007
11	ApolipoproteinsIBA 11/2022 - 12/2013
9	Proteins (Proteins, Gene)FDA Link 01/2022 - 04/2013
8	LigandsIBA 01/2021 - 11/2009
6	4- (N- methylamino)- 4'- (2- (2- (2- fluoroethoxy)ethoxy)ethoxy)stilbeneIBA 01/2022 - 02/2008
6	CopperIBA 01/2018 - 01/2010
5	Vesicular Monoamine Transport Proteins (Vesicular Monoamine Transporter)IBA 10/2020 - 02/2010
5	Peptides (Polypeptides)IBA 05/2017 - 01/2011
4	LipidsIBA 11/2022 - 05/2017
4	Biological ProductsIBA 01/2022 - 10/2011
4	SynucleinsIBA 01/2021 - 11/2009
4	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 11/2017 - 04/2007
3	Monoamine Oxidase (MAO)IBA 10/2022 - 01/2022
3	Blood Proteins (Serum Proteins)IBA 01/2022 - 01/2017
3	Neurotransmitter Agents (Neurotransmitter)IBA 01/2022 - 11/2009
3	RadiopharmaceuticalsIBA 01/2021 - 08/2010
3	THK5351IBA 04/2020 - 11/2017
3	tau Proteins (tau Protein)IBA 01/2019 - 01/2010
3	Glucose (Dextrose)FDA LinkGeneric 11/2017 - 08/2002
3	Brain-Derived Neurotrophic Factor (BDNF)IBA 11/2017 - 11/2013
3	florbenazine F 18IBA 11/2017 - 07/2011
3	2- (4- aminophenyl)- 6- (2- fluoroethoxy)quinolineIBA 05/2014 - 04/2011
2	quinolineIBA 10/2022 - 11/2017
2	Glial Fibrillary Acidic ProteinIBA 01/2022 - 11/2021
2	KynurenineIBA 01/2022 - 10/2021
2	Protein AggregatesIBA 01/2021 - 01/2016
2	Protein Isoforms (Isoforms)IBA 01/2021 - 01/2019
2	AntibodiesIBA 01/2021 - 01/2014
2	CarbonIBA 01/2019 - 08/2007
2	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 01/2018 - 08/2013
2	StilbenesIBA 03/2015 - 08/2010
2	AD 20 (AD-20)IBA 01/2012 - 07/2011
2	alpha-SynucleinIBA 09/2009 - 09/2007
2	Nicotinic Receptors (Nicotinic Acetylcholine Receptor)IBA 01/2006 - 08/2005
1	Cholinergic Agents (Cholinergics)IBA 01/2022
1	Muscarinic M4 ReceptorIBA 10/2021
1	Arginine (L-Arginine)FDA Link 10/2021
1	CreatinineIBA 10/2021
1	CitrullineIBA 10/2021
1	N,N-dimethylarginine (asymmetric dimethylarginine)IBA 10/2021
1	Biogenic Amines (Biogenic Amine)IBA 10/2021
1	symmetric dimethylarginineIBA 10/2021
1	Amino Acids FDA Link 10/2021
1	AsparagineIBA 10/2021
1	acylcarnitineIBA 10/2021
1	Threonine (L-Threonine)FDA Link 10/2021
1	Hydroxyproline (4 Hydroxyproline)IBA 10/2021
1	Proline (L-Proline)FDA Link 10/2021
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 10/2021
1	Phenylalanine (L-Phenylalanine)FDA Link 10/2021
1	PresenilinsIBA 01/2021
1	Coffee FDA Link 01/2021
1	Dopamine (Intropin)FDA LinkGeneric 01/2021
1	Presenilin-2IBA 01/2021
1	NeurograninIBA 01/2021
1	Pyrrolidonecarboxylic Acid (Pyroglutamic Acid)IBA 01/2021
1	Testosterone (Sustanon)FDA Link 01/2021

Therapy/Procedure

8	Therapeutics 01/2018 - 06/2006
4	Secondary Prevention 01/2020 - 01/2013
2	Immunotherapy 01/2014 - 09/2011
1	Denervation 01/2022